Has Kent Logan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,836 in general payments to Kent Logan, MD across 97 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kent Logan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kent Logan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kent Logan, MD

Neurology · Hampton, NHNPI 1992765200

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Lundbeck LLC accounts for 60.4% of it on its own, with 7 other manufacturers making up the rest.

$1,836in general payments, 2019–2025

Across 97 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lundbeck LLC$1K
AbbVie$352
Siemens Medical Solutions USA, Inc.$151
Biogen$122
Sanofi$41
Kyowa Kirin, Inc.$34
plus $28 from 2 others

What the payments were for

Food & beverage$1,836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lundbeck LLC	60	$1,109
AbbVie	21	$352
Siemens Medical Solutions USA, Inc.	3	$151
Biogen	7	$122
Sanofi	2	$41
Kyowa Kirin, Inc.	2	$34
Sanofi-aventis U.S. LLC	1	$15
Almatica Pharma LLC	1	$13

How this compares

$1,836 in reported general payments places this provider in the 75th percentile of 92 neurology providers in New Hampshire.

See all neurology providers in New Hampshire →

Medicare billing

Part B allowed, 2024

$190,312

Medicare patients

347

Services billed

69,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AubagioTeriflunomide	26	$226,102
Avonex Pen (4 Pack)Interferon Beta-1a	25	$201,570
Kesimpta PenOfatumumab	11	$86,843
CopaxoneGlatiramer Acetate	14	$81,598
Nurtec OdtRimegepant Sulfate	14	$47,470
Dimethyl Fumarate	19	$25,768
Carbidopa-LevodopaCarbidopa/Levodopa	138	$6,165
Levetiracetam	64	$4,706
Dalfampridine ErDalfampridine	19	$4,308
Gabapentin	143	$3,547
Memantine Hcl	37	$2,325
Rasagiline Mesylate	13	$1,989
Pregabalin	48	$1,570
Primidone	42	$1,544
AmantadineAmantadine Hcl	26	$1,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
SanofiAubagio	$41	$226,10226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 neurology providers in New Hampshire.

Other neurology in Hampton

Ann CabotManchester$622K
Oliver PhillipsLebanon$50K
Andrew PachnerLebanon$31K
Jeffrey RindDerry$27K
Uladzimir LuchanokDerry$21K
John RescignoDerry$20K
Jeffrey CohenLebanon$18K
Jacob KaufmanNashua$17K
Jianhui ZhangLebanon$12K
Chad MeshbergerConcord$10K

See the full list for New Hampshire →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →